📇 Rhumatologue · EVREUX CEDEX · (27) · Libéral
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
3 raisons identifiées
Praticien-chercheur
9 articles scientifiques publiés — formation continue solide
Disponibilité géographique
2 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
63.9 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CH EURE SEINE EVREUX
ZAC DE CAMBOLLE R LEON SCHWARTZENBERG, 27015 EVREUX CEDEX
CABINET PRIVE DU DR ANAS MEHDAOUI
ZAC DE CAMBOLLE CENTRE HOSPITALIER SAINT-LOUIS RUE LEON SCHWARTZENBERG, 27015 EVREUX CEDEX
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Arthritis & rheumatology (Hoboken, N.J.) · 2016
ObjectiveIntravenous immunoglobulin (IVIG) represents a therapeutic alternative in antineutrophil cytoplasmic antibody–associated vasculitides (AAV), but its efficacy has been evaluated in only 2 small prospective trials. The aim of this study was to evaluate the efficacy and safety of IVIG in patients with AAV.MethodsWe conducted a nationwide retrospective study of patients who received IVIG as immunomodulatory therapy for AAV.ResultsA total of 92 patients (mean age 51 years) presenting with either granulomatosis with polyangiitis (Wegener's) (68%), eosinophilic granulomatosis with polyangiitis (Churg‐Strauss) (22%), or microscopic polyangiitis (10%) received at least 1 course of IVIG. Antineutrophil cytoplasmic antibodies were present in 72% during the flare that required IVIG, as determined by immunofluorescence assay. IVIG was initiated because of relapsing disease in 83% of cases. IVIG was given for a median of 6 months (range 1–156 months) and in combination with corticosteroids in 21% of the patients or with other immunosuppressive agents in 77%. Efficacy of IVIG was assessed in the entire population and in a subset of 34 patients with unmodified background therapy. Remission rates at 6 months were 56% in the entire population and 58% in the unmodified background therapy group. Refractory disease and treatment failure at 6 months were observed in 7% and 18% in the whole population and 3% and 21% in the unmodified background therapy group, respectively. Adverse events (AEs) occurred in 33%, including serious AEs in 12% and AEs leading to discontinuation of IVIG in 7%.ConclusionThis large study shows the clinical benefit of IVIG as adjunctive therapy, with an acceptable tolerance profile, and thus supports its use in AAV patients with refractory or relapsing disease.
Medicine · 2016
The European respiratory journal · 2024
BackgroundSeveral rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.MethodsWe conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.ResultsWe identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).ConclusionsThe high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
The European respiratory journal · 2024 · Journal Article
Brudon A, Legendre M, Mageau A, Bermudez J, et al.
Respirology (Carlton, Vic.) · 2023 · Multicenter Study
Lachkar S, Roger M, Vergnon JM, Crutu A, et al.
Respiratory medicine and research · 2023 · Review
Cottin V, Bonniaud P, Cadranel J, Crestani B, et al.
The journal of allergy and clinical immunology. In practice · 2020 · Journal Article
David C, Jachiet M, Pineton de Chambrun M, Gamez AS, et al.
Medicine · 2016 · Journal Article
Ghrenassia E, Mekinian A, Chapelon-Albric C, Levy P, et al.
Arthritis & rheumatology (Hoboken, N.J.) · 2016 · Journal Article
Crickx E, Machelart I, Lazaro E, Kahn JE, et al.
The American journal of medicine · 2015 · Case Reports
Dion J, Terrier B, Jaïs X, Mehdaoui A, et al.
The American journal of medicine · 2007 · Case Reports
Marie I, Levesque H, Manrique A, Vera P, et al.
Lung cancer (Amsterdam, Netherlands) · 2004 · Journal Article
Grivaux M, Breton JL, Bombaron P, Kuntz P, et al.